Daily Archives: January 12, 2023
RCT | A 24-week, all-oral regimen for rifampin-resistant tuberculosis
12 Jan, 2023 | 13:27h | UTCA 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis – New England Journal of Medicine
Commentary: Trial results show superiority of shorter, all-oral treatment for drug-resistant TB – CIDRAP
WHO consolidated guidelines on tuberculosis | Drug-resistant tuberculosis treatment, 2022 update
12 Jan, 2023 | 13:30h | UTCSee also:
– WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment
RCT | Early treatment with Molnupiravir did not reduce hospitalizations in high-risk adults with COVID-19
12 Jan, 2023 | 13:24h | UTCCommentaries:
Molnupiravir doesn’t cut Omicron hospitalization, death but can speed recovery – CIDRAP
The dangers of non-randomized, observational studies: experience from the COVID-19 epidemic
12 Jan, 2023 | 13:26h | UTC
An evidence and consensus-based definition of “Second Victim”
12 Jan, 2023 | 13:21h | UTC
Cohort Study | Risk factors for suffocation and unexplained causes of infant deaths
12 Jan, 2023 | 13:18h | UTCRisk Factors for Suffocation and Unexplained Causes of Infant Deaths – Pediatrics
Commentary: Risk Factors for Sleep-Related Suffocation, Infant Death Identified – HealthDay
Commentary on Twitter
In 2019, ~3,400 US families experienced the loss of an infant due to sudden death, including accidental suffocation in bed, SIDS, & unknown causes. This case-control study was initiated to improve understanding & inform prevention strategies: https://t.co/dlEGtapqDI #Pediatrics pic.twitter.com/IywHPXTohJ
— AAP Pediatrics (@aap_peds) December 5, 2022
RCT | Planned delivery for pre-eclampsia between 34 and 37 weeks of gestation
12 Jan, 2023 | 13:20h | UTCOriginal Publication: Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial – The Lancet
RCT | Effect of pessary vs. surgery in patients with symptomatic pelvic organ prolapse
12 Jan, 2023 | 13:16h | UTCEffect of Pessary vs Surgery on Patient-Reported Improvement in Patients With Symptomatic Pelvic Organ Prolapse: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Commentary: Findings question value of pessary for pelvic organ prolapse – MDedge
Commentary on Twitter
In this study, among patients with symptomatic pelvic organ prolapse, an initial strategy of pessary therapy, compared with surgery, did not meet criteria for noninferiority with regard to patient-reported improvement at 24 months. https://t.co/PRb7iclR8O pic.twitter.com/ex3SSmLqyz
— JAMA (@JAMA_current) December 20, 2022
SR | Diagnostic errors in the emergency department
12 Jan, 2023 | 13:19h | UTC
RCT | Effect of a biopsychosocial intervention vs. postural therapy in patients with acute and subacute spine pain
12 Jan, 2023 | 13:15h | UTCEffect of a Biopsychosocial Intervention or Postural Therapy on Disability and Health Care Spending Among Patients With Acute and Subacute Spine Pain: The SPINE CARE Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
See also: Visual Abstract
Commentary: Noninvasive Interventions Can Reduce Spine Pain Versus Usual Care – HealthDay
Commentary on Twitter
Among patients with acute or subacute spine pain, both a biopsychosocial intervention and a postural therapy intervention resulted in modest statistically significant reductions in disability at 3 months compared with usual care. https://t.co/vwRa4UNkSk pic.twitter.com/rtm2zixVln
— JAMA (@JAMA_current) December 22, 2022
ASCO Living Guideline | Therapy for stage IV non–small-cell lung cancer without driver alterations
12 Jan, 2023 | 13:12h | UTCEditorial: ASCO Living Guidelines: The Next Frontier
ASCO Living Guideline | Therapy for stage IV non–small-cell lung cancer with driver alterations
12 Jan, 2023 | 13:13h | UTCEditorial: ASCO Living Guidelines: The Next Frontier
NCCN Guideline | Pediatric central nervous system cancers
12 Jan, 2023 | 13:11h | UTCEditorial: ASCO Living Guidelines: The Next Frontier
Cohort Study | Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in MS
12 Jan, 2023 | 13:09h | UTC
Commentary on Twitter
Study suggests that presenting with progression independent of relapse activity (PIRA) after a first demyelinating event in multiple sclerosis is an unfavorable long-term prognosis, especially if it occurs early in the disease course. https://t.co/Mao0Wf8GXI
— JAMA Neurology (@JAMANeuro) December 19, 2022
RCT | Tenecteplase does not improve outcomes in patients with wake-up stroke assessed by non-contrast CT
12 Jan, 2023 | 13:08h | UTCSafety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial – The Lancet Neurology (free for a limited period)
Commentary on Twitter
Here's the result from the TWIST trial, link is available for reading in the Lancet Neurology for 50 days.
Spoiler alert: 0,25 mg/kg, max 25 mg tenecteplase does not improve outcome in wake-up stroke (selected with non-contrast CT of the brain).https://t.co/eCDINM0a1k— Erik Lundström (@lundstrom_erik) December 20, 2022
RCT | Second-line levofloxacin-based quadruple therapy vs. bismuth-based quadruple therapy for Helicobacter pylori eradication
12 Jan, 2023 | 13:06h | UTCSecond-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
New research – Liou et al – Second-line levofloxacin-based quadruple therapy vs bismuth-based quadruple therapy for H pylori eradication and long-term changes to the gut #microbiota and antibiotic resistome: an RCThttps://t.co/Aipu3TRyFr#Hpylori #microbiome #AMR @emadelomar pic.twitter.com/aeFMAI3FCj
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) December 20, 2022
SR | Interventions for the eradication of methicillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis
12 Jan, 2023 | 13:04h | UTC
SR | Laser therapy for retinopathy in sickle cell disease
12 Jan, 2023 | 13:02h | UTCLaser therapy for retinopathy in sickle cell disease – Cochrane Library
Summary: Laser therapy for retinopathy in sickle cell disease – Cochrane Library
M-A | Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy effects on obesity comorbidities
12 Jan, 2023 | 13:00h | UTC
Phase 1-2 study | Lentiviral gene therapy for artemis-deficient SCID
12 Jan, 2023 | 12:59h | UTCLentiviral Gene Therapy for Artemis-Deficient SCID – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Infant gene therapy is a breakthrough for Artemis-SCID patients – University of California – San Francisco
Commentary on Twitter
Severe combined immunodeficiency caused by mutations in the gene encoding a DNA-repair enzyme called Artemis is difficult to treat. This study involving 10 patients supports a gene-therapy approach. https://t.co/SCpZjOQtMW pic.twitter.com/VRYOje6UPV
— NEJM (@NEJM) December 22, 2022
M-A | Blood endotoxin levels as biomarker of non-alcoholic fatty liver disease
12 Jan, 2023 | 12:57h | UTC
Phase 2 RCT | Upfront autologous HSCT vs. carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in multiple myeloma
12 Jan, 2023 | 12:56h | UTCInvited Commentary: Upfront autologous transplantation still improving outcomes in patients with multiple myeloma – The Lancet Haematology
M-A | The prevalence of obesity among children with type 2 DM
12 Jan, 2023 | 12:53h | UTCCommentary: Not All Pediatric Cases of Type 2 Diabetes Have Obesity – HealthDay
Commentary on Twitter
Meta-analysis finds that 75% of children with type 2 diabetes have obesity; not all pediatric T2DM patients have obesity. Further studies are needed to investigate the mechanisms beyond obesity driving this condition in children. https://t.co/RsDVSDq7rq
— JAMA Network Open (@JAMANetworkOpen) December 16, 2022
Phase 2 RCT | No benefit from the Bruton’s tyrosine kinase inhibitor Evobrutinib in systemic lupus erythematosus
12 Jan, 2023 | 12:54h | UTC
Review | Antithrombotic therapy after bioprosthetic aortic valve replacement
12 Jan, 2023 | 12:51h | UTC